|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
RU2607038C2
(ru)
|
2011-02-28 |
2017-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Антигенсвязывающие белки
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
AR103477A1
(es)
*
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
EP3150636A1
(en)
*
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
KR102799807B1
(ko)
|
2015-12-30 |
2025-04-24 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
EP3433281A1
(en)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
CN110402253B
(zh)
*
|
2017-03-10 |
2024-01-05 |
豪夫迈·罗氏有限公司 |
用于生产多特异性抗体的方法
|
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
|
KR102294136B1
(ko)
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
항-lag3 항체
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス， インコーポレイテッド |
骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
|
|
CN110799540B
(zh)
*
|
2017-06-25 |
2024-02-13 |
西雅图免疫公司 |
多特异性抗体及其制备和使用方法
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019122052A2
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/wt1
|
|
EP3731865A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche AG |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
CN111630063A
(zh)
|
2018-01-31 |
2020-09-04 |
豪夫迈·罗氏有限公司 |
稳定化的免疫球蛋白结构域
|
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
CN111936625B
(zh)
|
2018-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
调节哺乳动物细胞中的生乳活性
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
KR20240155361A
(ko)
|
2018-12-21 |
2024-10-28 |
에프. 호프만-라 로슈 아게 |
Cd3에 결합하는 항체
|
|
PH12021551470A1
(en)
|
2018-12-21 |
2022-04-11 |
Hoffmann La Roche |
Antibody that binds to vegf and il-1beta and methods of use
|
|
SG11202106525TA
(en)
*
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Multispecific binding proteins with mutant fab domains
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
CN114127113A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与钙网蛋白结合的多功能分子及其用途
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
AU2020226904B2
(en)
|
2019-02-21 |
2025-05-01 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN114127111B
(zh)
|
2019-02-21 |
2024-09-10 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
CN114981286A
(zh)
|
2019-05-03 |
2022-08-30 |
豪夫迈·罗氏有限公司 |
降低从纯化平台获得的组合物中酶水解活性速率的方法
|
|
BR112021021673A2
(pt)
|
2019-05-09 |
2021-12-21 |
Genentech Inc |
Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo
|
|
CN114702587A
(zh)
*
|
2019-05-09 |
2022-07-05 |
美勒斯公司 |
用于使蛋白质多聚化的变体结构域及其分离
|
|
MX2021015057A
(es)
*
|
2019-06-13 |
2022-01-18 |
Allogene Therapeutics Inc |
Anticuerpos anti-talen y usos de los mismos.
|
|
HUE071032T2
(hu)
|
2019-06-26 |
2025-07-28 |
Hoffmann La Roche |
Emlõs sejtvonalak SIRT-1 gén kiiktatásával
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
MY206610A
(en)
|
2019-07-31 |
2024-12-26 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
BR112022004972A2
(pt)
|
2019-09-18 |
2022-06-28 |
Genentech Inc |
Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
EP4057980A1
(en)
|
2019-11-15 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in aqueous protein solutions
|
|
JP7415005B2
(ja)
|
2019-12-18 |
2024-01-16 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｃｌ２抗体
|
|
BR112022011854A2
(pt)
|
2019-12-18 |
2022-09-06 |
Hoffmann La Roche |
Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
|
|
WO2021133723A2
(en)
|
2019-12-23 |
2021-07-01 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
KR20220129003A
(ko)
|
2020-01-15 |
2022-09-22 |
에프. 호프만-라 로슈 아게 |
재조합 단백질 제조 공정으로부터 불순물을 감소시키기 위한 방법
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
|
WO2021198034A1
(en)
|
2020-03-30 |
2021-10-07 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf and pdgf-b and methods of use
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
|
WO2021233853A1
(en)
|
2020-05-19 |
2021-11-25 |
F. Hoffmann-La Roche Ag |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
|
US20230340081A1
(en)
|
2020-06-08 |
2023-10-26 |
Hoffmann-La Roche Inc. |
Anti-hbv antibodies and methods of use
|
|
MX2022015887A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1.
|
|
US11780920B2
(en)
|
2020-06-19 |
2023-10-10 |
Hoffmann-La Roche Inc. |
Antibodies binding to CD3 and CD19
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
CA3176579A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
CA3184747A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
KR20230047361A
(ko)
|
2020-07-01 |
2023-04-07 |
아르스 파마슈티컬스 인크. |
항-asgr1 항체 접합체 및 이의 용도
|
|
WO2022008468A1
(en)
|
2020-07-07 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
EP4204458A4
(en)
|
2020-08-26 |
2024-10-09 |
Marengo Therapeutics, Inc. |
METHODS FOR DETECTION OF TRBC1 OR TRBC2
|
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
|
|
IL300616A
(en)
|
2020-09-04 |
2023-04-01 |
Hoffmann La Roche |
Antibody that binds to VEGF-A and ANG2 and methods of use
|
|
MX2023003328A
(es)
|
2020-09-24 |
2023-03-27 |
Hoffmann La Roche |
Lineas de celulas de mamifero con desactivacion genica.
|
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
|
EP4263609A1
(en)
|
2020-12-17 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Anti-hla-g antibodies and use thereof
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック， インコーポレイテッド |
抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
|
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
|
WO2022214565A1
(en)
|
2021-04-09 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
KR20230173164A
(ko)
|
2021-04-19 |
2023-12-26 |
제넨테크, 인크. |
변형된 포유류 세포
|
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CN117500829A
(zh)
|
2021-06-18 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
US20230197278A1
(en)
|
2021-07-13 |
2023-06-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
JP2024528217A
(ja)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗体および使用方法
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
EP4416301B1
(en)
|
2021-12-21 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Method for the determination of hydrolytic activity
|
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗ｎｏｔｃｈ２抗體及結合物及其使用方法
|
|
CN119421890A
(zh)
|
2022-04-19 |
2025-02-11 |
豪夫迈·罗氏有限公司 |
改进的生产细胞
|
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
CR20250056A
(es)
|
2022-07-22 |
2025-03-19 |
Genentech Inc |
Moléculas de unión al antígeno anti-steap1 y sus usos.
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
EP4602371A1
(en)
|
2022-10-12 |
2025-08-20 |
F. Hoffmann-La Roche AG |
Method for classifying cells
|
|
IL320073A
(en)
|
2022-11-23 |
2025-06-01 |
Hoffmann La Roche |
Method for increasing recombinant protein expression
|
|
CN119546630A
(zh)
|
2022-12-08 |
2025-02-28 |
南京诺唯赞生物科技股份有限公司 |
特异性结合rsv的抗体
|
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
EP4676519A1
(en)
|
2023-03-06 |
2026-01-14 |
F. Hoffmann-La Roche AG |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
EP4676951A1
(en)
|
2023-03-10 |
2026-01-14 |
Genentech Inc. |
Fusions with proteases and uses thereof
|
|
CN120936626A
(zh)
|
2023-03-31 |
2025-11-11 |
基因泰克公司 |
抗αvβ8整合素抗体及使用方法
|
|
CN121127493A
(zh)
|
2023-05-08 |
2025-12-12 |
豪夫迈·罗氏有限公司 |
靶向干扰素 α 融合蛋白及使用方法
|
|
AU2024311704A1
(en)
|
2023-06-22 |
2026-01-08 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
AU2024323186A1
(en)
|
2023-08-09 |
2026-01-15 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|